Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Just released on company site.

    Sentiment: Buy

  • better buy into gale asap in that case, June could see lift off possibly akin to cpxx, just started looking around for where to put some new money and came across ecyt as a Baker Bros. holding, thanks for the info on this thread all. time for serious dd and decisions. ....and another of my long plays with an imminent catalyst, by end of June if not sooner is mstx, could be the first new drug for sickle cell in 17 years, ph.3 readout any day. good luck.

  • SO....ECYT has made a gradual move up this week, no doubt because of their presentation at ASCO. Anyone reliable out there going to be able to give unbiased update on their presentation? I have been in this stock for two years and not much has happened. Smile...I follow your posts, but sometimes think you might be a little jaded to the positive side of things. I do wonder why if ECYT drug is so good, why aren't more insiders buying? It is a legit question....there has to be some insider who feels positive about their drug.

  • Endocyte Incorporated registered a decrease of 3.88% in short interest. ECYT’s total short interest was 3.70 million shares in June as published by FINRA. Its down 3.88% from 3.85 million shares, reported previously. With 190,600 shares average volume, it will take short sellers 19 days to cover their ECYT’s short positions. The short interest to Endocyte Incorporated’s float is 10.87%

  • 100-300 share sells, then buys, back and forth. Can't see how anyone makes any money doing that :)

  • Obviously you haven't been following for long or don't grasp what has taken place the last few years.

    Sentiment: Strong Buy

  • rxdavemull@sbcglobal.net rxdavemull May 28, 2016 7:21 PM Flag

    If ECYT has a great pipeline then why is the stock at $3.87? 3 years is a quick time period in biotech.I would gladly buy more at this price if I could get wnywhere near $12 in just 3 years.

    Sentiment: Strong Buy

  • Reply to

    Partner

    by carpfarmer11 May 27, 2016 10:18 AM

    they come from bms and will go back i think to bms or combat with merck

  • Who would make the best partner for ECYT? They will probably be a lot of talk after next Sunday.

  • Reply to

    ASCO 1169

    by prestroke May 26, 2016 7:20 AM

    news from yesterday compared with nivolumab (opdivo) progression free was 3month and quote from stabil disease 30% if we design 1b with fr ++ and get PR plus higher dosis 15,5mg or 19mg than we get what we want 80-150$ thats for sure

    Sentiment: Strong Buy

  • Abstract:

    Background: The folate receptor (FR) is highly expressed in several epithelial cancers (e.g. ovarian, NSCLC) but is expressed at low levels in most normal tissues. EC1456 is a novel, next generation SMDC of folic acid and the potent cytotoxic agent tubulysin B hydrazide (TubBH). EC1456 targets folate receptor positive (FR+) tumors to deliver TubBH intracellularly, leading to mitotic inhibition. Etarfolatide is a folate-containing tracer that chelates technetium-99m for SPECT imaging. 99mTc-etarfolatide non-invasively identifies FR+ malignant lesions to select pts for FR-targeted treatment. Phase 2 studies with the first generation therapeutic folate SMDC vintafolide have shown its utility in patient selection for FR-targeted therapy. Methods: The primary objective is to determine the MTD of EC1456 administered on 2 schedules BIW: days 1, 4, 8, 11 q 21 or 28 days (dosages: 0.5-4.5 mg/m2), or QW: days 1, 8 q 21 days (dosages: 1.5-10.0 mg/m2). Key inclusion criteria include: age ≥ 18 years, ECOG PS 0–1, and adequate end-organ function. 99mTc-etarfolatide scan to evaluate FR status is obtained on enrolled pts. Dose escalation follows the “3+3” protocol. Cycle 1 DLT evaluation must be completed for each dose level prior to dosing a new cohort. Results: 46 pts have been treated and are evaluable for cycle 1 toxicity. Median age is 66.5 years (range: 39-86); 27 pts are female. 23 pts have received 93 cycles of EC1456 BIW (median: 2; range: 1-22), and 23 pts have received 87 cycles of EC1456 QW (median: 2; range: 1-18). There have been no treatment-related deaths. One pt experienced uncomplicated G4 neutropenia. Two DLT’s have been observed, both on the QW schedule: G3 infusion reaction (4.5 mg/m2), and G3 headache (10.0 mg/m2). Stable disease (SD) 4 months has been observed in 3 FR+ pts (mesothelioma, GEJ CA, SCLC) on the BIW schedule, and in 1 FR+ NSCLC pt and 1 FR non-evaluable pt with leiomyosarcoma on the QW schedule. Conclusions: Overall, both schedules of EC1456 appear to be well tolerated. Dose escalation is ongoing on both schedules. Anti-tumor activity of EC1456 is suggested by durable SD in pts with FR+ disease. Pharmacokinetic analyses are ongoing. Clinical trial information: NCT01999738

  • Not questioning the possibility of what you're saying....but moved most of my biotech money from here to other stocks that have upcoming catalysts (within 3-4 months). This is moving at an agonizing snails pace. Plenty of time to jump in later....

    Sentiment: Hold

  • Fine, I'll grab a glass.

  • Again everyone wants instant gratification with returns. This would have been the case with ECYT had it not been for the over selling and shorting following PROCEED halting. They found out too late it was due to the control arm abnormality. With advancements ECYT has had since that time, we would probably already be at the levels I mentioned. A $100 price is an approx. $4.2B cap. 145 in one indication was valued over $1B for PROC. A more successful drug for more indications with greater success should, through common sense math, surpass that figure. Take into consideration 1169, and the new anti-PD1, as well as the anti-inflammatory drugs entering trials this year and you have significantly more than $4B valuation. Ill be happy to share the koolaid. I've been investing in bio's for some time, but I have never been as optimistic about potential as I am with ECYT. Regarding buyout; no big pharma is going to buy out a developing bio until candidates are proven or near ready for market. By then the price has already increased to the costly point and directors will ask for the future value of company. That is where you see a price double or triple over night. There will not be a buyout at a $1B or $2B cap. I can tell you with great certainty that they are not looking to sell the company until value is maximized with pipeline.

    Sentiment: Strong Buy

  • I have been predicting for some time that short interest would hit bottom in Jan/Feb 2016 since the original timeline for 1456 Phase 1A was dosing by EOY2015, and data by ASCO 2016. ECYT then revised their timeline early 2016 to "maybe" dosing by ASCO (June 3-7) and data by EOY 2016. Likewise it appears wall street had already revised their shorting agenda to fall in line with ASCO deadline, as short interest dropped 3.9% to lowest levels realized even before PROCEED on 5/13 report. Wall Street was expecting something from ASCO 6 months ago. Means nothing other than supporting the long running 24 month manipulation / agenda of ECYT. Price has and will continue to stabilize as fewer and fewer covers are needed. When there is little need for low price covering in addition to increased demand on news; we will see substantial price gains with upcoming key milestones. Volume has been fairly balanced, but I predict 10 day average to lower slightly more as need for manipulation loosens. Everyone will start showing their "love" for ECYT again to drive up demand since the shorts and manipulators back peddled their way out of this mess they created in 2014. I am fairly confident that everything will change course starting with ASCO.

    Sentiment: Strong Buy

  • i guarantee we'll see $20. Just can't say when. Best guess is a couple of years considering 1456 is running behind. Of course much higher is possible but i hate pump monkeys so stick to what i'm confident with.

  • wow, I'm bullish on $ECYT but damn, smile share some of that koolaid. I cover (okay make a little) at $12 and that's with over 12+ months of ownership. Not fun!!! I'd love to see share prices at $100 ... I just don't see a path to that. IMO, they'd be bought out well before that.

    Sentiment: Buy

  • Reply to

    Why is the Board so quiet?

    by andauiado May 18, 2016 8:44 PM

    Excited for ASCO!! Board won't be quiet soon

  • Who said anything about 200%? Surely your not listening to an analyst? Lets remember that we saw over $28 on the thought that 145 would be advanced in one indication. 1456 is same target, same market, same linker, all proven platform, with a stronger warhead dosing now at levels which saw curable activity in lab with no side effects. Why would you even think that $12, less than half of max seen for 145 in one indication, would be the long term target? All of this without the most recent late braking posters for anti-PD1, not to mention the hint which was dropped on earnings call that referenced unsolicited calls hinting around partnership for the presented drug posters. With 145, even analysts were talking $65 (short term) for PROC indication. I can tell you many in industry were talking over $100 long term. Because of 1456, 1169, and newest candidates recently presented; both will be dramatically increased with time. The question is will that time be 12, 24, 36 months? That is the unknown here. Not if they will be successful, just how long the process will take. $12 will be a joke, and the current price in the $3's will be hysterical, a few years from now. I am in for the long haul to the imminent buyout.

    Sentiment: Strong Buy

  • Reply to

    Why is the Board so quiet?

    by andauiado May 18, 2016 8:44 PM

    I think schadenfreude8 provides very good opinions regarding your questions. We live in a society that seeks immediate gratification. If turning a quick buck is not imminent; you will not catch much attention. The attention ECYT does have is from many investors that know and understand that PROCEED was halted for an abnormal result in the control arm, NOT the drug testing arm. The drug performed just as well as it did in all historical trials there deemed a success by the market and industry. So lets be very clear, minus a control arm abnormality there have been no setbacks in the development of the ECYT pipe. Their choice to advance 1456 over 145 did two things;it provided time for manipulation following incorrect action by Wall Street following the PROCEED halting and before we knew why it was halted. It also allowed for covering as can be seen in short interest figures over last 24 months, but very noticeable following ASCO 2014 when GOOD news sent the price down while short interest surged. Short interest has now bottomed as data on 1456 was expected by ASCO. Volume has also dropped, which suggests major covering complete and positions are holding long. In my opinion, there has also been little interest due to the wall street agenda. Lets think common sense; if you made bad calls, over shorted for next 12 months, you would need the price to stay low. If you follow volume, price, and short interest with key dates you can see the manipulation over last 24 months quite easily. If you need it to stay low; who are you going to tell? You need to cover first so you keep your lips shut. At the same time, we found out why PROCEED was halted, so again you keep your lips sealed to keep away fund competition. So you have some that need to cover, and you want to do better than their competition on wall street. Once that is done, which again seems to be the case just right before ASCO by coincidence, they can sit back and watch it rise again. BBros. caught on :)

    Sentiment: Strong Buy

Must Watch
ECYT
3.21-0.06(-1.83%)4:00 PMEDT